R3i Previous events
1 September 2019
Addressing residual vascular risk :
Is a new therapy on the horizon?
R31 & IAS Press Conference
Paris, France
24 November 2018
The Selective Peroxisome Proliferator-Activated Receptor Alpha Modulator (SPPARMa) Concept
New Joint Initiative of the International Atherosclerosis Society (IAS) and Residual Risk Reduction Initiative (R3i) on the concept of SPPARM-a
Chantilly, France
10 June 2017
MSDA 2017 - 12th Metabolic Syndrome, type II Diabetes and Atherosclerosis Congress
MSDA 2017 - 12th Metabolic Syndrome, type II Diabetes and Atherosclerosis Congress
Saint Petersburg, Russia
28 November 2014
VAS and R3i Multidisciplinary Joint Scientific Session “Residual Risk”
VAS 11th European Angiology Days
Uggiate Trevano (Como), Italy
18 September 2014
Preventive cardiology R3i session
PEDIM 2014 - Prague European Days of Internal Medicine
Prague, Czech Republic
12 September 2014
MSDA Kyoto 2014 - A highlight of R3i activities
9th Metabolic syndrome, Type 2 Diabetes and Atherosclerosis Congress (MSDA 2014)
Kyoto, Japan
29 July 2014
CASMU R3i Symposium : Una actualización en dislipemias aterogénicas
La formación médica continua de la Escuela de Graduados, por encargo del Departamento de Cardiología de CASMU
Montevideo, Uruguay
22 March 2014
R3i Goes Global: Latin America launch at SOCESP
Sociedade de Cardiologia do Estado de Sao Paulo Congress (SOCESP 2014)
Sao Paulo, Brazil
4 October 2013
R3i symposium : Residual Risk – What does it mean? How to influence it?
12th European Congress of Internal Medicine
Prague, Czech Republic